ISTOCK, OONAL
Questions Raised About “Breakthrough” Therapies’ Clinical Support
Questions Raised About “Breakthrough” Therapies’ Clinical Support
Compared to other drugs, therapeutics given breakthrough status receive FDA approval on the basis of weaker trial evidence, a study finds.
Questions Raised About “Breakthrough” Therapies’ Clinical Support
Questions Raised About “Breakthrough” Therapies’ Clinical Support

Compared to other drugs, therapeutics given breakthrough status receive FDA approval on the basis of weaker trial evidence, a study finds.

Compared to other drugs, therapeutics given breakthrough status receive FDA approval on the basis of weaker trial evidence, a study finds.

breakthrough therapy
Picking Up the Pace
Picking Up the Pace
Kate Yandell | Jan 1, 2016
FDA designations promise to expedite the approval of drugs for conditions ranging from infectious disease to cancer.
Speaking of Science
Speaking of Science
The Scientist Staff | Jan 1, 2016
January 2016's selection of notable quotes